**Combinostics**

1 solution for 3 disciplines: cNeuro

Platform for interdisciplinary clinical work in radiology, neurology, nuclear medicine

OUR VISION

We simplify complexity, empowering healthcare professionals to make evidence-based medical decisions with confidence.

OUR PRODUCTS

Explore how our cNeuro brain quantification software (cMRI, cPET, and cDAT) and clinical decision support tool (cDSI) can help transform the way healthcare professionals diagnose and monitor neurological disorders.

Access the cNeuro Web-Viewer from anywhere

Flexible workflow

Robust quantification of MRI, PET and SPECT brain images

Clinical decision support: imaging + clinical data

www.combinostics.com

Combinostics

cNeuro cMRI cDSI cPET cDAT

Your radiology companion: cMRI
Automated MRI quantification for neurological disorders

Your benefits

cMRI provides fully automated quantification of T1 and FLAIR images. Individual patient results are compared to a large reference database of >10K healthy controls.

Why use cMRI?

■ **Precise quantification.** Fully automated accurate and robust quantification of T1 and FLAIR images.

■ **Concise and detailed reporting.** Results include brain volumes, lesion counts and size, and disease-specific imaging biomarkers.

■ **Efficient and configurable workflows.** Upload of data for processing with reports and segmentation maps sent back to PACS without any manual steps.

■ **cNeuro Viewer.** Access to our Web-based Viewer for deeper insights & interdisciplinary communication.

Our Reports:

- **Dementia Report.** Automatic quantification of brain volumes and dementia-specific imaging biomarkers (global cortical atrophy, medial temporal lobe atrophy, brain tissue white matter hyperintensities, anterior-posterior score, callosal angle)

- **Dementia Patient Report.** Patient-oriented report including visualizations that can be discussed with the patient

- **MS Report.** Cross-sectional and longitudinal lesion count and size quantification. Segmentation maps illustrate the distribution of lesion in space (deep white matter, juxta-cortical, periventricular, infratentorial) and time (new, growth, stable, shrinking).

- **Atrophy and Lesion Report Cross-Sectional/Longitudinal Report.** Specifically designed report without disease-specific wording including volumetry and lesion quantification.

- **Parkinson+ Report.** Automatic quantification of subcortical volumes, area of midbrain and pons, midbrain-to-pons-ratio, and cortical asymmetry for differential diagnosis of Parkinson Plus syndromes.

- **TBI Report.** Automatic quantification of an extended set of brain volumes highlighting tissue loss and swelling. Lesions in commonly affected regions such as the corpus callosum are quantified.

- **Epilepsy Report.** Automatic quantification of hippocamal asymmetry.

- **Brain Health Report.** Specifically designed report for brain health check-ups.

CE 0598

www.combinostics.com

FDA CLEARED

Your clinical companion: cDSI

Clinical decision-support in dementia by combining imaging and clinical data

Your benefits

cDSI compares individual patient results to a database with information from previously diagnosed dementia patients. It supports clinical decision-making in differential diagnostics and prediction of progression.

Why use cDSI?

- **Combination of imaging and clinical data.** cDSI allows to combine imaging data with clinical data (demographics, clinical and neuropsychological tests, cerebrospinal fluid biomarkers, genetic data). ◎ VIEW MORE

- **Differential diagnostics:** Decision models to differentiate Alzheimer's disease, frontotemporal dementia, vascular dementia, and cognitively normal. ◎ VIEW MORE

- **Evaluation of disease progression.** Quantitative support for determining progression from mild cognitive impairment to Alzheimer's disease within the next two years. ◎ VIEW MORE

- **Computerized decision support regarding additional testing.** Simulation regarding whether additional amyloid testing should be considered. ◎ VIEW MORE

- **cNeuro Viewer.** Access to our Web-based Viewer for deeper insights & interdisciplinary communication.

www.combinostics.com

Combinostics

cNeuro
cMRI
cDSI
cPET
cDAT

Your nuclear medicine companion for Dementia: cPET

Automated Amyloid and FDG PET quantification

Your benefits

cPET is a fully automated tool for PET brain quantification in nuclear medicine.

Why use cPET?

- **Standardized reporting & Centiloids**. Possibility for FDG and Amyloid PET processing; comparison with tracer-specific reference data (FDG, Flutemetamol, Florbetapir, Florbetaben) and Centiloid quantification for Amyloid.

- **PET-only and PET-MR Workflow.** If the patient's MRI is available, PET regions are based on segmented MRI structures and the MRI is also used for visualization purposes.

- **Precise quantification.** Unique image registration technique allows for increased accuracy and confidence.

- **cNeuro viewer.** Access to our Web-based Viewer for deeper insights & interdisciplinary communication.

CE 0598

FDA CLEARED

www.combinostics.com